NCT03422679 - Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 5, 2017

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions

Breast CancerColorectal CancerAdenoid Cystic CarcinomaNon-hodgkin LymphomaGlomus Tumor, MalignantHepatocellular CarcinomaOsteosarcomaT-ALL

Interventions

DRUG

CB-103

Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.

Trial Locations (17)

6500

Oncology Institute of Southern Switzerland, Bellinzona

9007

Kantonsspital St.Gallen, Sankt Gallen

10117

Charite- Universitaetsmedizin Berlin- Campus Benjamin Franklin, Berlin

28034

Hospital Ramón y Cajal, Madrid

60590

Universitätsklinikum Frankfurt, Frankfurt

69120

Nationales Centrum für Tumorerkrankungen Heidelberg, Heidelberg

75475

Hôpital Saint-Louis, Paris

77030

MD Anderson, Houston

90403

Sarcoma Oncology Research Center, Santa Monica

02215

Dana-Farber Cancer Institute, Boston

Unknown

Centre Hospitalier Lyon-Sud, Lyon

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital - Yonsei Cancer Center, Seoul

06351

Seoul National University Hospital, Seoul

08023

Hospital Quirón Barcelona, Barcelona

08035

Vall d'Hebron Institute of Oncology (VHIO), Barcelona

08916

Catalan Institute of Oncology, Barcelona